Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ITRM

Iterum Therapeutics Plc

Jun 18 • 04:00PM ET

0.9970

Dollar change +0.0170
Percentage change 1.73	%

Healthcare • Biotechnology • Ireland • NASD

Peers: QURE ENTA PTGX AXSM VSTM FATE CORT TVRD KPTI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.00	Insider Own	2.19%	Shs Outstand	40.00M	Perf Week	-4.13%
Market Cap	39.88M	Forward P/E	-	EPS next Y	-0.07	Insider Trans	0.00%	Shs Float	39.13M	Perf Month	0.04%
Income	-22.56M	PEG	-	EPS next Q	-0.11	Inst Own	1.93%	Short Float	2.75%	Perf Quarter	-31.24%
Sales	0.00M	P/S	-	EPS this Y	57.87%	Inst Trans	-4.25%	Short Ratio	2.25	Perf Half Y	-44.61%
Book/sh	-0.07	P/B	-	EPS next Y	82.67%	ROA	-85.79%	Short Interest	1.08M	Perf Year	-14.79%
Cash/sh	0.32	P/C	3.15	EPS next 5Y	55.20%	ROE	-555.68%	52W Range	0.81 - 3.02	Perf YTD	-43.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	29.27%	ROIC	-76.89%	52W High	-66.99%	Beta	2.82
Dividend TTM	-	Quick Ratio	3.58	Sales past 5Y	-	Gross Margin	-	52W Low	23.39%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	3.72	EPS Y/Y TTM	62.29%	Oper. Margin	-	RSI (14)	48.85	Volatility	2.23% 2.67%
Employees	9	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	68.79%	Payout	-	Rel Volume	0.50	Prev Close	0.98
Sales Surprise	-	EPS Surprise	28.57%	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	477.57K	Price	1.00
SMA20	1.90%	SMA50	-3.93%	SMA200	-26.07%	Trades		Volume	237,318	Change	1.73%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-21	Upgrade	Gabelli & Co	Sell → Hold
Mar-15-21	Upgrade	H.C. Wainwright	Neutral → Buy	$2.50
Jun-02-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$7 → $2
Jan-21-20	Downgrade	Gabelli & Co	Buy → Sell
Dec-11-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-21-19	Initiated	H.C. Wainwright	Buy	$17

Jun-11-25 07:00AM	Iterum Therapeutics Announces Partnership for Commercialization Services (GlobeNewswire)
May-19-25 07:00AM	Iterum Therapeutics Announces Extension of Term of Promissory Note (GlobeNewswire)
May-14-25 03:08AM	Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
02:52AM	Q1 2025 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
May-13-25 07:00AM	Iterum Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire) -7.09%
07:00AM	Loading…
May-06-25 07:00AM	Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire) -5.09%
Apr-30-25 04:30PM	Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) +5.66%
Apr-29-25 08:00AM	Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares (GlobeNewswire) -15.87%
Apr-14-25 08:00AM	Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics (GlobeNewswire)
Feb-08-25 02:06AM	Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
12:16AM	Q4 2024 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Feb-07-25 07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-31-25 08:00AM	Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025 (GlobeNewswire)
Nov-21-24 08:30AM	Iterum Therapeutics Regains Full Nasdaq Compliance (GlobeNewswire) +8.59%
Nov-15-24 02:10AM	Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... (GuruFocus.com)
07:00AM	Loading…
Nov-14-24 07:00AM	Iterum Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-11-24 08:00AM	Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 (GlobeNewswire)
Oct-28-24 10:19AM	FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships (Benzinga) -23.94%
07:49AM	FDA approves Iterums ORLYNVAH NDA for uUTI treatment (Pharmaceutical Technology)
05:00AM	Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections (PR Newswire)
Oct-25-24 11:03AM	Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections (GlobeNewswire) +60.68%
Oct-10-24 08:30AM	Iterum Therapeutics to Present Data at IDWeek 2024 (GlobeNewswire)
Oct-09-24 05:00PM	Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire) -5.01%
Sep-24-24 10:33AM	Iterums oral sulopenem acceptance hinges on antibiotic stewardship efforts (Pharmaceutical Technology)
Sep-10-24 07:00AM	Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women (GlobeNewswire) -12.04%
Sep-06-24 04:30PM	Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-17-24 08:09AM	Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-14-24 07:00AM	Iterum Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-10-24 08:18AM	Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q2 2024 Earnings Call Transcript (Insider Monkey)
Aug-07-24 04:30PM	Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 (GlobeNewswire)
05:30PM	Loading…
Aug-06-24 05:30PM	Iterum Therapeutics Announces Expiration and Results of Rights Offering (GlobeNewswire)
Aug-02-24 08:00AM	Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem (GlobeNewswire)
Jul-22-24 07:30AM	Iterum Therapeutics Commences Rights Offering (GlobeNewswire)
Jun-21-24 08:00AM	Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections (GlobeNewswire) +7.83%
Jun-05-24 08:00AM	Iterum Therapeutics to Present Data at ASM Microbe 2024 (GlobeNewswire)
May-31-24 08:00AM	Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections (GlobeNewswire) +16.28%
May-14-24 08:21AM	Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-13-24 10:49PM	Q1 2024 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
11:53AM	ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
07:00AM	Iterum Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 08:00AM	Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
Apr-29-24 08:00AM	Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem (GlobeNewswire) -7.78%
Apr-02-24 10:22AM	Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 12:09AM	Q4 2023 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 11:53AM	ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-21-24 04:30PM	Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024 (GlobeNewswire)
Mar-15-24 08:00AM	Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat (GlobeNewswire)
Mar-07-24 07:57AM	Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up (Zacks)
Mar-06-24 08:00AM	Iterum Therapeutics Provides Business Update (GlobeNewswire) +17.79%
Feb-01-24 03:03PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLC (GuruFocus.com)
Jan-30-24 07:00AM	Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections (PR Newswire) -11.73%
Dec-04-23 08:00AM	Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule (GlobeNewswire)
Nov-15-23 12:22PM	Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.76%
12:08AM	Q3 2023 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 07:00AM	Iterum Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-07-23 08:30AM	Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023 (GlobeNewswire)
Oct-24-23 08:00AM	Iterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections (GlobeNewswire) +6.87%
Oct-12-23 09:15AM	Iterum Therapeutics to Present Data at IDWeek 2023 (GlobeNewswire)
Aug-11-23 10:10PM	Q2 2023 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents) +7.92% -9.17%
07:00AM	Iterum Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 05:00PM	Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023 (GlobeNewswire)
Jun-27-23 09:50AM	Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89% (Zacks)
Jun-21-23 08:35AM	Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera (Zacks)
Jun-12-23 06:23PM	Iterum Therapeutics to Present Data at ASM Microbe 2023 (GlobeNewswire)
May-12-23 07:00AM	Iterum Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-10-23 09:16AM	Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat (Zacks)
Apr-20-23 05:00PM	Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials (GlobeNewswire) -5.04% -5.31%
Apr-13-23 12:00PM	All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy (Zacks) +8.27%
Mar-18-23 02:06AM	Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 09:16PM	Q4 2022 Iterum Therapeutics PLC Earnings Call (Thomson Reuters StreetEvents) +15.00% -6.09%
07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-09-23 05:00PM	Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023 (GlobeNewswire) -8.70% -8.57%
Jan-11-23 06:00PM	Iterum Therapeutics Reports Employment Inducement Grant (GlobeNewswire) +12.50%
Dec-15-22 08:00AM	Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem (GlobeNewswire) +6.14%
Nov-10-22 07:00AM	Iterum Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-03-22 08:00AM	Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022 (GlobeNewswire)
Oct-20-22 07:30AM	Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections (GlobeNewswire) -5.56%
Oct-17-22 05:19PM	Iterum Therapeutics to Present Data at IDWeek 2022 (GlobeNewswire) +6.06%
Sep-19-22 07:30AM	Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem (GlobeNewswire)
Sep-07-22 09:15AM	Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +7.98%
Sep-01-22 04:15PM	Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule (GlobeNewswire) -6.51%
Aug-17-22 09:45AM	Iterum Therapeutics (NASDAQ:ITRM) Has Debt But No Earnings; Should You Worry? (Simply Wall St.) -19.24%
Aug-16-22 09:00PM	Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split (GlobeNewswire)
Aug-12-22 07:00AM	Iterum Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-11-22 02:31PM	Iterum Therapeutics Shares Are Surging - Read Why (Benzinga) +40.42%
07:30AM	Iterum Therapeutics Announces Special Protocol Assessment (SPA) Agreement With the FDA (GlobeNewswire)
Jul-06-22 04:30PM	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.33%
Jun-14-22 05:00PM	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-22 07:00AM	Iterum Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) +7.84%
May-11-22 08:00AM	Iterum Therapeutics Provides Regulatory Update (GlobeNewswire) -11.37%
Apr-25-22 05:06PM	Iterum Therapeutics Presented Data at the 32nd European Congress of Clinical Microbiology and Infectious Diseases (GlobeNewswire) -6.69%
Mar-28-22 10:19AM	Iterum Expects To Start Additional Sulopenem Trial In Urinary Tract Infections In 2H22 (Benzinga) -14.27%
07:00AM	Iterum Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-21-22 08:00AM	Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022 (GlobeNewswire)
Mar-10-22 08:00AM	Iterum Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (GlobeNewswire)
Feb-08-22 05:00PM	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
Dec-14-21 04:30PM	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.63%
07:12AM	Is Iterum Therapeutics (NASDAQ:ITRM) Weighed On By Its Debt Load? (Simply Wall St.)
Dec-13-21 08:00AM	Iterum Therapeutics Appoints Sailaja Puttagunta, MD as Chief Medical Officer (GlobeNewswire)

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ITRM

Iterum Therapeutics Plc

Upgrade your FINVIZ experience